Karyopharm Therapeutics

$12.70
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.49 (-3.71%) As of 6:27 PM UTC today

Why Robinhood?

You can buy or sell KPTI and other stocks, options, and ETFs commission-free!

About KPTI

Karyopharm Therapeutics Inc. Common Stock, also called Karyopharm Therapeutics, is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA. The listed name for KPTI is Karyopharm Therapeutics Inc. Common Stock.

CEO
Michael G. Kauffman
Employees
347
Headquarters
Newton, Massachusetts
Founded
2008
Market Cap
960.93M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.72M
High Today
$13.20
Low Today
$12.65
Open Price
$13.18
Volume
1.73M
52 Week High
$28.04
52 Week Low
$12.65

KPTI Earnings

-$0.98
-$0.65
-$0.33
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 5, Pre-Market

You May Also Like

GM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure